Table 4 CpGs differentially methylated in association with incident coronary/cardiovascular disease in the fixed-effects meta-analyses of the samples from the Women’s Health Initiative (WHI) and the Framingham Offspring Study (FOS)
From: DNA methylation biomarkers of myocardial infarction and cardiovascular disease
Genomic information | Model 1 | Model 2 | Model 3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CpG | Chr* | Position (bp) | Gene | Coef* | SE* | P | Coef* | SE* | P | Coef* | SE* | P |
Incident coronary heart disease | ||||||||||||
cg21566642 | 2 | 233,284,661 | Intergenic | − 1.34 × 10–1 | 4.33 × 10–2 | 2.00 × 10–3 | − 9.63 × 10–2 | 4.83 × 10–2 | 4.62 × 10–2 | − 9.66 × 10–2 | 5.39 × 10–2 | 7.32 × 10–2 |
cg05575921 | 5 | 373,378 | AHRR | − 1.80 × 10–1 | 4.73 × 10–2 | 1.38 × 10–4 | − 1.33 × 10–1 | 5.81 × 10–2 | 2.21 × 10–2 | − 1.22 × 10–1 | 6.52 × 10–2 | 6.05 × 10–2 |
cg25769469 | 5 | 71,643,841 | PTCD2 | − 2.62 × 10–1 | 7.94 × 10–2 | 9.67 × 10–4 | − 2.52 × 10–1 | 8.02 × 10–2 | 1.70 × 10–3 | − 2.14 × 10–1 | 8.89 × 10–2 | 1.59 × 10–2 |
cg04988978 | 17 | 56,359,578 | MPO | − 2.28 × 10–1 | 7.49 × 10–2 | 2.29 × 10–3 | − 2.07 × 10–1 | 7.58 × 10–2 | 6.19 × 10–3 | − 1.06 × 10–1 | 8.35 × 10–2 | 2.03 × 10–1 |
Incident cardiovascular disease | ||||||||||||
cg21566642 | 2 | 233,284,661 | Intergenic | − 1.68 × 10–1 | 3.97 × 10–2 | 2.34 × 10–5 | − 1.31 × 10–1 | 4.40 × 10–2 | 2.94 × 10–3 | − 1.37 × 10–1 | 4.85 × 10–2 | 4.87 × 10–3 |
cg05575921 | 5 | 373,378 | AHRR | − 2.08 × 10–1 | 4.30 × 10–2 | 1.30 × 10–6 | − 1.67 × 10–1 | 5.24 × 10–2 | 1.42 × 10–3 | − 1.61 × 10–1 | 5.79 × 10–2 | 5.54 × 10–3 |
cg25769469 | 5 | 71,643,841 | PTCD2 | − 1.92 × 10–1 | 7.27 × 10–2 | 8.40 × 10–3 | − 1.77 × 10–1 | 7.35 × 10–2 | 1.58 × 10–2 | − 1.26 × 10–1 | 8.09 × 10–2 | 1.20 × 10–1 |
cg04988978 | 17 | 56,359,578 | MPO | − 2.04 × 10–1 | 6.72 × 10–2 | 2.42 × 10–3 | − 1.83 × 10–1 | 6.79 × 10–2 | 6.99 × 10–3 | − 9.08 × 10–2 | 7.36 × 10–2 | 2.18 × 10–1 |